Patient Subjective Assessment of Drug Side Effects in Inflammatory Bowel Disease

Background and Goals Side effects occur with every class of inflammatory bowel disease (IBD) medication. Our goal was to assess IBD patients' subjective assessment of drug side effects using the [Sid]e [e]ffects [s]urvey (SidES), a survey instrument that we previously developed and tested in patients with asthma and psychiatric disorders. Study Disease activity, quality of life, and adherence was assessed in adult outpatients with IBD. SidES assesses the number, severity, and duration of side effects. Prescription and over the counter medications were evaluated. Results Thirty-nine patients from the University of Maryland IBD program participated. Twenty-two patients with Crohn's disease, 12 with ulcerative colitis, and 7 with indeterminate colitis were evaluated. Twenty-seven patients reported drug side effects, of which 56% reported changes in medical management. Disease activity increased, medication number increased, and quality of life decreased with increasing side effects scores. The number of medications and IBD drugs, use of steroids, and use of neuropsychiatrics correlated with side effects scores. Side effects scores negatively correlated with the quality of life. Conclusions Side effects were common in patients with IBD from a tertiary referral center. Side effects are not trivial for they can result in alterations in the medical regimen and are associated with increased disease activity and decreased quality of life scores. The total number of medications and use of neuropsychiatric drugs and steroids are correlated with side effects scores. Given the difficulty that patients have in determining whether a symptom is related to a particular drug or from a medical condition, further prospective studies are needed to evaluate the impact of patient assessment of side effects on clinical outcomes in IBD.

[1]  C. Seal,et al.  The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis , 2001, American Journal of Gastroenterology.

[2]  N. Laird,et al.  Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention , 1995 .

[3]  D. Binion,et al.  Polypharmacy and Crohn's disease , 2005, Alimentary pharmacology & therapeutics.

[4]  S. Hanauer,et al.  Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease , 1991, Drug safety.

[5]  G. Porro,et al.  Comparative Tolerability of Therapies for Ulcerative Colitis , 2002, Drug safety.

[6]  D. Bates,et al.  Incidence and preventability of adverse drug events among older persons in the ambulatory setting. , 2003, JAMA.

[7]  F. Di Mario,et al.  What do patients want to know about their inflammatory bowel disease? , 1992, The Italian journal of gastroenterology.

[8]  S. Hanauer,et al.  Comparative Tolerability of Treatments for Inflammatory Bowel Disease , 2000, Drug safety.

[9]  D. Classen,et al.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.

[10]  G. Lichtenstein,et al.  Corticosteroids in Crohn’s disease , 2002, American Journal of Gastroenterology.

[11]  L. Green,et al.  Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence , 1986, Medical care.

[12]  J. Rochon,et al.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.

[13]  T. Hausken,et al.  Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease , 2005, Scandinavian journal of gastroenterology.

[14]  K. Saeian,et al.  Increased Rates of Early Adverse Reaction to Azathioprine in Patients with Crohn's Disease Compared to Autoimmune Hepatitis: A Tertiary Referral Center Experience , 2005, The American Journal of Gastroenterology.

[15]  Joseph Finkelstein,et al.  How do psychiatric patients perceive the side effects of their medications , 2006 .

[16]  S. Hanauer,et al.  Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. , 2003, The American journal of medicine.

[17]  S. Hanauer,et al.  Treatment of inflammatory bowel disease: safety and tolerability issues. , 2003, The American journal of gastroenterology.

[18]  S D Small,et al.  Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. , 1995, JAMA.

[19]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[20]  E. G. Hahn,et al.  Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk? , 2001, Alimentary pharmacology & therapeutics.

[21]  R. Pounder,et al.  A simple clinical colitis activity index , 1998, Gut.

[22]  D. Binion,et al.  Narcotic use in patients with Crohn's disease , 2003, American Journal of Gastroenterology.

[23]  P. Banks,et al.  Are Patients with Inflammatory Bowel Disease Receiving Optimal Care? , 2005, The American Journal of Gastroenterology.

[24]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[25]  Olivia Carter-Pokras,et al.  Prescribing Patterns and Awareness of Adverse Effects of Infliximab: A Health Survey of Gastroenterologists , 2007, Digestive Diseases and Sciences.

[26]  S. Hanauer,et al.  Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis , 2001, American Journal of Gastroenterology.

[27]  E. Irvine,et al.  The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. , 1996, The American journal of gastroenterology.

[28]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.